Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development company, is pleased to announce the expansion of its clinical service subsidiary - Emerald Clinics - with the addition of a second consulting suite in Perth. The expansion comes off the back of record patient appointments in January 2021 and a recently announced expansion in Victoria. (See ASX release 09 Feb 21)
The Perth expansion will boost clinical capacity in WA and support Emyria to:
Improve patient access to Emerald Clinics services
Conduct pivotal clinical trials currently being planned for Emyria’s first drug development program, EMD-003, targeting unmet needs in mental health and seeking registration as a Schedule 3 medicine. (See ASX release 05 Jan 21)
Deliver on a recently awarded grant from the WA Government. The grant award of $880,000 was won with research partner, the University of Western Australia. Emyria’s technology and team will play a lead role monitoring the clinical and mental health of vulnerable patients remotely (see ASX release 05 Feb 21)
Emyria’s Managing Director, Dr Michael Winlo, said: “Western Australia was the first Emerald Clinics location. Demand for our services from both patients and referring doctors has grown every month since we opened. We anticipate this expansion will allow us to improve our waiting times and see more patients which, in turn, improves our proprietary data asset (Emyria Data).
Insights from Emyria Data is now informing the design and planning of pivotal drug registration clinical trials for our first drug program, EMD-003 - a cannabinoid medicine targeting unmet needs in mental health. The additional clinical capacity in Perth also allows us to support a wider range of clinical trials in different indications as well as help us deliver on the recently awarded Future Health Research and Innovation Grant involving our TGA-Registered remote monitoring system.”